Anthony J. Doyle
2021
Compensation breakdown
| Bonus | $19,632 |
|---|---|
| Non-Equity Incentive Plan | $220,860 |
| Option Awards | $1,287,761 |
| Salary | $490,800 |
| Stock Awards | $857,250 |
| Other | $14,500 |
| Total | $2,890,803 |
Doyle received $1.3M in option awards, accounting for 45% of the total pay in 2021.
Doyle also received $19.6K in bonus, $220.9K in non-equity incentive plan, $490.8K in salary, $857.3K in stock awards and $14.5K in other compensation.
Rankings
In 2021, Anthony J. Doyle's compensation ranked 4,577th out of 12,415 executives tracked by ExecPay. In other words, Doyle earned more than 63.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,577 out of 12,415 | 63rd |
Division Manufacturing | 1,897 out of 5,505 | 66th |
Major group Chemicals And Allied Products | 793 out of 2,375 | 67th |
Industry group Drugs | 707 out of 2,096 | 66th |
Industry Biological Products, Except Diagnostic Substances | 179 out of 449 | 60th |
Pay ratio
| Anthony J. Doyle's Pay | $2,890,803 |
|---|---|
| Median Employee's Pay | $273,522 |
| Pay Ratio | 11to 1 |
In 2021, the annual total compensation of Anthony J. Doyle was $2,890,803.
The annual total compensation of the median employee at BioCryst Pharmaceuticals was $273,522.
The ratio of Anthony J. Doyle's pay to the pay of median employee was therefore 11 to one.
Doyle's colleagues
We found five more compensation records of executives who worked with Anthony J. Doyle at BioCryst Pharmaceuticals in 2021.
2021
Megan Sniecinski
BioCryst Pharmaceuticals
Former Chief Business Officer
2021
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2021
Helen Thackray
BioCryst Pharmaceuticals
Chief R&D Officer
2021
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
2021
Yarlagadda Babu
BioCryst Pharmaceuticals